Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Moxalactam. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 1/20 | 0.99 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.79 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.79 |
| ▸ | CMA1 | P23946 | 18/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Moxalactam SCHEMBL951857 | 1.00 | PTGS1 (0.99) | PTGS1HSD17B10TDP1CMA1 | |
| Moxalactam SCHEMBL951858 | 1.00 | PTGS1 (0.99) | PTGS1HSD17B10TDP1CMA1 | |
| Moxalactam SCHEMBL10694935 | 1.00 | PTGS1 (0.99) | PTGS1HSD17B10TDP1CMA1 | |
| Moxalactam SCHEMBL9800360 | 0.99 | PTGS1 (0.97) | PTGS1HSD17B10TDP1CMA1 | |
| Moxalactam SCHEMBL194013 | 0.99 | PTGS1 (1.00) | PTGS1HSD17B10TDP1CMA1 | |
| Moxalactam SCHEMBL14196602 | 0.99 | PTGS1 (1.00) | PTGS1HSD17B10TDP1CMA1 | |
| Moxalactam SCHEMBL194012 | 0.99 | PTGS1 (1.00) | PTGS1HSD17B10TDP1CMA1 | |
| Moxalactam SCHEMBL49016 | 0.99 | PTGS1 (1.00) | PTGS1HSD17B10TDP1CMA1 | |
| Moxalactam SCHEMBL49017 | 0.99 | PTGS1 (1.00) | PTGS1HSD17B10TDP1CMA1 | |
| Moxalactam SCHEMBL3382938 | 0.92 | PTGS1 (0.87) | PTGS1HSD17B10TDP1CMA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 109 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2953624-B1 | METHODS OF TREATING MICROBIAL INFECTIONS, INCLUDING MASTITIS | LUODA PHARMA LTD (IE) | 2019-08-21 | — | — | EP | claimed |
| CN-105492004-A | Method of treating topical microbial infections | LUODA PHARMA PTY LTD | 2016-04-13 | — | — | CN | claimed |
| CN-105492005-A | Methods of treating microbial infections including mastitis | LUODA PHARMA PTY LTD | 2016-04-13 | — | — | CN | claimed |
| US-20160000748-A1 | METHODS OF TREATING TOPICAL MICROBIAL INFECTIONS | Luoda Pharma Limited (IE) | 2016-01-07 | — | — | US | claimed |
| US-20150366797-A1 | METHODS OF TREATING MICROBIAL INFECTIONS, INCLUDING MASTITIS | Luoda Pharma Limited (IE) | 2015-12-24 | — | — | US | claimed |
| EP-2953623-A1 | METHODS OF TREATING TOPICAL MICROBIAL INFECTIONS | Luoda Pharma Pty Ltd (AU) | 2015-12-16 | — | — | EP | claimed |
| EP-2953624-A1 | METHODS OF TREATING MICROBIAL INFECTIONS, INCLUDING MASTITIS | Luoda Pharma Pty Ltd (AU) | 2015-12-16 | — | — | EP | claimed |
| WO-2014121342-A1 | METHODS OF TREATING TOPICAL MICROBIAL INFECTIONS | LUODA PHARMA PTY LIMITED (AU) | 2014-08-14 | — | — | WO | claimed |
| US-8273712-B2 | Promoting wound healing by administering a prostaglandin E and granulocyte-macrophage colony stimulating factor | MEDICAL RESEARCH COUNCIL (GB) | 2012-09-25 | — | — | US | claimed |
| US-8012967-B2 | Minor groove binders | UNIVERSITY OF STRATHCLYDE (GB) | 2011-09-06 | — | — | US | claimed |
| US-20080317705-A1 | Promoting Wound Healing by Administering a Prostaglandin E and Granulocyte-Macrophage Colony Stimulating Factor | MEDICAL RESEARCH COUNCIL (UK) | 2008-12-25 | — | — | US | claimed |
| EP-1951259-A1 | PROMOTING WOUND HEALING BY ADMINISTERING A PROSTAGLANDIN E AND GRANULOCYTE-MACROPHAGE COLONY STIMULATING FACTOR | Medical Research Council (GB) | 2008-08-06 | — | — | EP | claimed |
| WO-2007060453-A1 | PROMOTING WOUND HEALING BY ADMINISTERING A PROSTAGLANDIN E AND GRANULOCYTE-MACROPHAGE COLONY STIMULATING FACTOR | MEDICAL RESEARCH COUNCIL (GB) | 2007-05-31 | — | — | WO | claimed |
| US-20250099395-A1 | HEMOSTATIC NANOCAPSULES FOR STOPPING BLEEDING, VISUALIZING INJURY, AND DELIVERING DRUGS | UNIV MARYLAND (US) | 2025-03-27 | — | — | US | disclosed |
| US-20250019417-A1 | NOVEL POLYPEPTIDES AND MEDICAL USES THEREOF | COLZYX AB (SE) | 2025-01-16 | — | — | US | disclosed |
| US-12171885-B2 | Hemostatic nanocapsules for stopping bleeding, visualizing injury, and delivering drugs | UNIVERSITY OF MARYLAND, BALTIMORE COUNTY (US) | 2024-12-24 | — | — | US | disclosed |
| WO-2004056828-A2 | NOVEL COMPOUNDS AND USES THEREOF | DESTINY PHARMA LIMITED (GB) | 2004-07-08 | — | — | WO | disclosed |
| WO-2003059881-A2 | DNA MINOR GROOVE BINDING COMPOUNDS | UNIVERSITY OF STRATHCLYDE (GB) | 2003-07-24 | — | — | WO | disclosed |
| WO-1999051253-A2 | IMMUNE RESPONSE MODULATION | IMPERIAL COLLEGE INNOVATIONS LTD. (GB) | 1999-10-14 | — | — | WO | disclosed |
| WO-1994013277-A2 | USE OF DINAPHTHALENES COMPOUNDS AS ANTIPROLIFERATIVE AGENTS | IMPERIAL CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 1994-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160000748-A1 | METHODS OF TREATING TOPICAL MICROBIAL INFECTIONS | TSLP, CCL11, IL17A | PTGS1 774/4885HSD17B10 1621/4885TDP1 3972/4885 |
| US-20150366797-A1 | METHODS OF TREATING MICROBIAL INFECTIONS, INCLUDING MASTITIS | LCT, TSLP, MLEC | PTGS1 959/4885HSD17B10 465/4885TDP1 4845/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.